Diclofenac Transdermal Patch: Critical Safety Concerns and Clinical Recommendations

Introduction to Safety Concerns

The American Heart Association warns that all NSAIDs, including diclofenac in any formulation, carry black box warnings for serious gastrointestinal adverse events, including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal and occur without warning symptoms 1
The American Heart Association also warns that NSAIDs, including diclofenac, carry black box warnings for increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal and may increase with duration of use 1

Diclofenac shows elevated cardiovascular risk compared to other NSAIDs, with meta-analyses demonstrating a relative risk of 1.63 (95% CI 1.12-2.37) for vascular events versus placebo and 1.54 (95% CI 1.23-1.93) for recurrent MI in registry data 1
Mortality risk with diclofenac is particularly concerning, with a relative risk of 2.40 (95% CI 2.09-2.80) in patients with cardiovascular disease 1

The American Heart Association recommends that NSAIDs should be used with extreme caution in patients with chronic renal failure, as they can impair renal function in patients with decreased effective circulating volume and promote sodium and water retention 2

The American Heart Association recommends considering acetaminophen up to 4g daily (monitor for blood pressure elevation in hypertensive patients) or non-pharmacologic modalities including heat therapy, massage, or physical therapy for localized musculoskeletal pain 2
The American Heart Association recommends using SSRIs (particularly sertraline for lower QTc risk) for neuropathic pain, as they are safe in cardiovascular disease 2
The American Heart Association recommends using low-dose immediate-release opioids without active metabolites (methadone, buprenorphine, or fentanyl) for severe pain, as they may be more appropriate in renal dysfunction than NSAIDs 2